NCT05725291招募中1 期
First-in-Human, Phase 1 Study of AMT-116 in Patients With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 80
- 试验地点
- 10
- 主要终点
- Recommended Phase 2 Dose (RP2D)
研究概览
简要总结
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-116, in Patients with Advanced Solid Tumors
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be willing and able to sign the ICF, and to adhere to the study visit schedule and other protocol requirements.
- •Age ≥18 years (at the time consent is obtained).
- •Patients with histologically confirmed, unresectable advanced solid tumor. Preferred tumor types include head and neck, non-small cell lung, esophageal, pancreatic, large cell lung, colorectal, cervical, breast, bladder, gastric, biliary tract, skin squamous cell, liver, and basal cell cancer.
- •Patients who have undergone at least one systemic therapy and have radiologically or clinically determined progressive disease during or after most recent line of therapy, and for whom no further standard therapy is available, or who are intolerable to standard therapy.
- •Patients must have at least one measurable lesion as per RECIST version 1.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-
- •Both male and female patients must agree to use effective contraceptive methods.
- •Patients must have adequate organ function.
- •Women of child-bearing potential (WCBP) must have a negative serum pregnancy test.
- •Male patients must agree to use a latex condom, even if they had a successful vasectomy, while on study treatment and for at least 12 weeks after the last dose of the IMP.
- •Male patients must agree not to donate sperm, and female patients must agree not to donate eggs, while on study treatment and for at least 12 weeks after the last dose of the IMP.
- •Availability of tumour tissue sample (either an archival specimen or a fresh biopsy material) at screening.
排除标准
- •Prior therapy with ADC based on Top1 inhibitor.
- •Central nervous system (CNS) metastasis.
- •Active or chronic skin disorder requiring systemic therapy.
- •History of Steven's Johnson's syndrome or Toxic Epidermal Necrolysis syndrome.
- •Active ocular conditions requiring treatment or close monitoring, including, but not limited to: macular degeneration, papilledema, active diabetic retinopathy with macular oedema, wet age-related macular degeneration requiring intravitreal injections, or uncontrolled glaucoma.
- •Persistent toxicities from previous systemic anti-neoplastic treatments of Grade >
- •Systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of the IMP.
- •Radiotherapy to lung field at a total radiation dose of ≥20 Gy within 6 months, wide-field radiotherapy (e.g., > 30% of marrow-bearing bones) within 28 days.
- •Major surgery (not including placement of vascular access device or tumor biopsies) within 28 days prior to the first dose of the IMP, or no recovery from side effects of such intervention.
- •Prior allogeneic or autologous bone marrow transplantation.
- •Significant cardiac disease, such as recent (within six months prior to first dose of the IMP) myocardial infarction or acute coronary syndromes (including unstable angina pectoris), congestive heart failure (New York Heart Association class III or IV), uncontrolled hypertension, uncontrolled cardiac arrhythmias.
- •Pregnant or breast-feeding females.
- •Note: Other protocol defined Inclusion/Exclusion criteria apply.
研究组 & 干预措施
AMT-116 Dose Escalation
Experimental
干预措施: AMT-116 (Drug)
结局指标
主要结局
Recommended Phase 2 Dose (RP2D)
时间窗: Up to 24 months
The RP2D will be determined using dose limiting toxicities (DLTs) and all other available study data
Maximum Tolerated Dose (MTD)
时间窗: Up to 24 months
The MTD will be determined using DLTs
Type, incidence and severity of Adverse Events
时间窗: Up to 24 months
Safety and tolerability profile assessed by the Common Terminology Criteria for Adverse Events v5.0
次要结局
- Maximum observed concentration (C[max])(Up to 24 months)
- Area under the curve (AUC)(Up to 24 months)
- Terminal half-life (t[1/2])(Up to 24 months)
- Concentration of anti-drug antibodies (ADA)(Up to 24 months)
- Overall Response Rate (ORR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1(Up to 24 months)
- Disease Control Rate (DCR) according to the RECIST v1.1(Up to 24 months)
- Progression-free Survival (PFS)(Up to 24 months)
- Time to maximum concentration (Tmax)(Up to 24 months)
研究者
研究点 (10)
Loading locations...
相似试验
招募中
1 期
AMT-151 in Patients With Selected Advanced Solid TumoursAdvanced Solid TumorAdvanced CancerAdvanced CarcinomaOvarian CarcinomaOvarian Epithelial CancerOvarian Endometrioid AdenocarcinomaEndometrial CancerEndometrial AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Endometrioid AdenocarcinomaEndometrial Clear Cell AdenocarcinomaOvarian CancerLung AdenocarcinomaTriple Negative Breast CancerPancreatic Ductal AdenocarcinomaOvarian Clear Cell AdenocarcinomaOvarian Mucinous AdenocarcinomaMalignant Pleural MesotheliomaOvarian Clear Cell CarcinomaNCT05498597Multitude Therapeutics Inc.30
招募中
1 期
AMT-253 in Patients With Selected Advanced Solid TumoursAdvanced Solid TumorNCT05906862Multitude Therapeutics (Australia) Pty Ltd54
招募中
1 期
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid TumoursAdvanced Solid TumorPDACHNSCCNCT06597721Adcendo ApS210
已完成
1 期
Dose-Seeking Study of MPT0E028 in Subjects With Advanced Solid Malignancies Without Standard TreatmentAdvanced Solid MalignanciesNCT02350868Taipei Medical University23
已完成
1 期
First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C MutationNeoplasmsAdvanced Solid TumorsColorectal CancerNon-small Cell Lung CancerNCT04006301Janssen Research & Development, LLC10